2019 Alzheimer’s Disease Therapeutics Industry

The report “Alzheimer’s Disease Therapeutics Market to 2019 – Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation″ by  GBI Research is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with Alzheimer’s disease Therapeutics Market to 2019 – Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation in subject line and your contact details to purchase this report or get your questions answered.

The collection of ‘Alzheimer Drugs’ market research reports has a new addition of “Alzheimer’s Disease Therapeutics Market to 2019 – Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation” on RnRMarketResearch.com. The Alzheimer’s disease (AD) market is characterized by a lack of products with strong disease-modifying properties and a number of high-profile product failures in late stages of development over recent years. In addition, recent or impending patent expiries for all of the four currently marketed products and a late-stage pipeline with limited-to-moderate prospects are expected to impede growth over the next few years. In the medium-term future, the market is expected to be characterized by substantial generic competition and overall decline. However, the current development pipeline shows signs of meaningful innovation, although the vast majority of these products are currently in the early stages of development. Despite one of the highest drug attrition rates across the industry, a number of innovative and potentially disease-modifying therapeutics are likely to enter the market and translate recent insights into the etiology of AD combined with an earlier therapeutic intervention into better products, which will begin to transform the AD market towards the end of the decade.

Request a sample copy of this report by GBI Research@ http://www.rnrmarketresearch.com/contacts/request-sample?rname=127325  .

Scope

• A brief introduction to AD etiology, pathogenesis, diagnosis, and treatment regimes
• Profiling of the marketed products in the AD market, including analysis of their safety, efficacy, treatment patterns, and strengths and weaknesses
• Comprehensive review of the pipeline for AD therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule type, and molecular target.
• Additional in-depth analysis of pipeline drug clinical trials, analyzed by phase, molecule type, trial size, trial duration and program failure rate, for each molecule type and mechanism of action
• Multi-scenario forecast data for the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets of the US, Japan, Germany, the UK, France, Italy and Spain
• Discussion of the drivers of and barriers to market growth
• Analysis of the licensing and co-development deals landscape

Complete report is available @ http://www.rnrmarketresearch.com/alzheimers-disease-therapeutics-market-to-2019-early-stage-innovation-points-to-disease-modifying-therapies-and-market-transformation-market-report.html . Read more on “Alzheimer’s Disease Therapeutics Market to 2019 – Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation” report below.

Reasons to Buy

• Understand the different levels of AD therapies, from early-stage or mild AD to severe AD
• Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
• Observe trends in terms of clinical trial duration and size among clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for AD therapeutics
• Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the AD therapeutics market

For further information on “Alzheimer’s Disease Therapeutics Market to 2019 – Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation” report OR for any other business research / market intelligence need on the ‘Alzheimer Drugs’ market (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/alzheimer-drugs .), contact sales@rnrmarketresearch.com / Call +1 888 391 5441.